Compare · MIRM vs NVS
MIRM vs NVS
Side-by-side comparison of Mirum Pharmaceuticals Inc. (MIRM) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MIRM and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $305.27B, about 47.9x MIRM ($6.37B).
- MIRM has hit the wire 12 times in the past 4 weeks while NVS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Mirum Pharmaceuticals Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $6.37B
- $305.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 25
Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest MIRM
- SVP, GLOBAL CONTROLLER Howe Jolanda exercised 40,000 shares at a strike of $6.27 and sold $4,000,000 worth of shares (40,000 units at $100.00) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Mirum Pharmaceuticals Inc.
- CHIEF FINANCIAL OFFICER Bjerkholt Eric sold $599,510 worth of shares (6,001 units at $99.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 36,355 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Peetz Christopher sold $1,978,402 worth of shares (20,000 units at $98.92) as part of a pre-agreed trading plan and exercised 20,000 shares at a strike of $2.94 (SEC Form 4)
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- SEC Form SCHEDULE 13G filed by Mirum Pharmaceuticals Inc.
- SVP, GLOBAL CONTROLLER Howe Jolanda sold $193,734 worth of shares (1,840 units at $105.29) as part of a pre-agreed trading plan, decreasing direct ownership by 59% to 1,274 units (SEC Form 4)
- SEC Form 10-Q filed by Mirum Pharmaceuticals Inc.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG